FindTrial
Sign In

A randomised double-blind controlled trial of BCNU as second-line therapy in metastatic oesophago-gastric, colorectal and pancreatic cancer

A randomised double-blind controlled trial of BCNU as second-line therapy in metastatic oesophago-gastric, colorectal and pancreatic cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN58648476
Enrollment
Unknown
Registered
2002-08-19
Start date
1995-01-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon, oesophagus, pancreas, rectum, stomach cancers Cancer

Interventions

1. Arm 1: BCNU 200 mg in 500 ml 5% dextrose 2. Arm 2: 5% dextrose alone

Sponsors

The Royal Marsden NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Any patient who has progressed on or has a short disease free interval with folinic acid modulated 5-Fluorouracil (5FU) protracted infusional 5FU regimens

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026